• FirefoxUpgrade to the new Firefox »
  •  Dow Down 1.45% Nasdaq Down 1.03%

    Progenics Pharmaceuticals, Inc. (PGNX)

    -NasdaqGS
    5.98 Down 0.27(4.32%) Jan 30, 4:00PM EST
    |After Hours : 5.98 0.00 (0.00%) Jan 30, 5:18PM EST
    Add to Portfolio
    Prev Close:6.25
    Open:6.21
    Bid:N/A
    Ask:8.49 x 200
    1y Target Est:7.50
    Beta:2.43
    Earnings Date:Mar 11 - Mar 16 (Est.)
    Day's Range:5.97 - 6.38
    52wk Range:3.10 - 7.84
    Volume:767,059
    Avg Vol (3m):1,107,850
    Market Cap:415.94M
    P/E (ttm):49.83
    EPS (ttm):0.12
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    » More Headlines for PGNX

    Comparison

    Symbol% ChgMkt Cap
    PGNXDown 4.32%415.94M
    DNDN 0.00%N/A
    NKTRDown 2.79%1.88B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):9.07
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-14) :0.13
    Quarterly EPS Est (Dec-14) :-0.13
    Mean Recommendation*:2.3
    PEG Ratio (5 yr expected):1.92

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback